Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

Background Exenatide (exendin‐4) exhibits dose‐dependent glucoregulatory activity, but causes dose‐limiting nausea and vomiting. This study was designed to formally assess the possibility of inducing tolerance to the side effects of nausea and vomiting at therapeutic doses of exenatide, using a dose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes/metabolism research and reviews Jg. 20; H. 5; S. 411 - 417
Hauptverfasser:	Fineman, Mark S., Shen, Larry Z., Taylor, Kristin, Kim, Dennis D., Baron, Alain D.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Chichester, UK John Wiley & Sons, Ltd 01.09.2004 Wiley
Schlagworte:	Adolescent Adult Aged Biological and medical sciences Blood Glucose - metabolism Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance dose-escalation Endocrine pancreas. Apud cells (diseases) Endocrinopathies exenatide exendin-4 Female Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects incretin mimetic Male Medical sciences Middle Aged mitigation of side effects Nausea - chemically induced Nausea - prevention & control Peptides - administration & dosage Peptides - adverse effects reduction of adverse events type 2 diabetes Venoms - administration & dosage Venoms - adverse effects Endocrinopathy Type 2 diabetes Human incretin mimetic Mimetic dose- escalation Exenatide reduction of adverse events Increasing dose Hypoglycemic agent Secondary effect mitigation of side effects exendin-4
ISSN:	1520-7552, 1520-7560
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!